The purpose of NCT03546686 is to determine the efficacy of cryoablation, ipilimumab, and nivolumab versus standard care on three-year OS, in patients with hormone receptor-negative, HER2-negative advanced breast cancer after neoadjuvant chemotherapy. This evidence concerns the gene ERBB2 and breast carcinoma.